drugset / Trial / NCT06434610
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Phase 2
Recruiting
90 enrolled
Shanghai Jiaolian Drug Research and Development Co., Ltd
Shanghai Pharmaceuticals Holding Co., Ltd · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.
Timeline
- Start
- 2024-07-11
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B013 | Unknown | 600 mg | Intravenous |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | — |
Indications
No indication recorded.